{
  "ticker": "AFP",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02964020",
  "id": "02964020",
  "pages": 4,
  "price_sensitive": false,
  "date": "20250701",
  "time": "0731",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250701/pdf/06l990zgn71gvv.pdf",
  "summary": "- **Combogesic IV (Maxigesic IV) launching in Canada** this month via AFT's new Canadian subsidiary (targeting non-opioid pain management market).  \n- **Extended US licensing agreement with Hikma Pharmaceuticals** for Maxigesic IV (Combogesic IV) and tablet form (Combogesic Rapid), restructuring profit share to quarterly payments.  \n- **R&D progress**:  \n  - Pre-IND filed with FDA for antibiotic eyedrop (targeting resistant infections); IND filing expected by year-end.  \n  - Pre-IND planned for topical Strawberry Birthmarks treatment in 2025.  \n  - IND planned for novel iron injection by end-2025.  \n  - Pipeline now includes 14 projects, 5 nearing commercialization.  \n- **Paediatric study for Maxigesic IV** to begin, expanding addressable market.  \n- **Five out-licensing deals completed** this quarter; additional agreements under negotiation.  \n\n*No material financial data (e.g., cash balance) or capital-raising details provided.*",
  "usage": {
    "prompt_tokens": 2424,
    "completion_tokens": 219,
    "total_tokens": 2643,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-30T22:00:12.181847"
}